These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15816509)

  • 1. Conivaptan Yamanouchi.
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conivaptan (Yamanouchi).
    Martinez-Castelao A
    Curr Opin Investig Drugs; 2002 Jan; 3(1):89-95. PubMed ID: 12054079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conivaptan: promise of treatment in heart failure.
    Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
    Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan (Otsuka).
    Doggrell SA
    Curr Opin Investig Drugs; 2004 Sep; 5(9):977-83. PubMed ID: 15503654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
    Ali F; Raufi MA; Washington B; Ghali JK
    Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
    Schwarz ER; Sanghi P
    Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conivaptan: YM 087.
    Drugs R D; 2004; 5(2):94-7. PubMed ID: 15293869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure].
    Yamamura Y; Sato O; Fujiki H
    Nihon Rinsho; 2007 May; 65 Suppl 5():164-8. PubMed ID: 17571379
    [No Abstract]   [Full Text] [Related]  

  • 12. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic use of vaptans for the treatment of dilutional hyponatremia.
    Cassagnol M; Shogbon AO; Saad M
    J Pharm Pract; 2011 Aug; 24(4):391-9. PubMed ID: 21813818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecule of the Month: Conivaptan hydrochloride.
    Drug News Perspect; 2006 Nov; 19(9):574. PubMed ID: 17220962
    [No Abstract]   [Full Text] [Related]  

  • 15. Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.
    Reilly T; Schork MR
    Ann Pharmacother; 2010 Apr; 44(4):680-7. PubMed ID: 20332337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    Palm C; Pistrosch F; Herbrig K; Gross P
    Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conivaptan (Vaprisol) for hyponatremia.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):51-2. PubMed ID: 16785851
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
    Goldsmith SR; Elkayam U; Haught WH; Barve A; He W
    J Card Fail; 2008 Oct; 14(8):641-7. PubMed ID: 18926434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaptans and the treatment of water-retaining disorders.
    Quittnat F; Gross P
    Semin Nephrol; 2006 May; 26(3):234-43. PubMed ID: 16713496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
    Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.